Zerigo Health
- Industry
- Medical Devices
- Founded Year
- 2014
- Headquarters
- San Diego, CA
- Employee Count
- 45
Key People
- Lisa Rometty - Chief Executive Officer
- John E. Schellhorn - President & Chief Executive Officer
- Remo Qajar - Co-Founder
- Keith Patton - VP Software Development
- Glen Tullman - Board Member
- Paul LaViolette - Board Member
- Christina LaMontagne - Board Member
- Michael Wasserman - Board Member
Assessment
- Team
-
Aspect: First-time 10+ yrs
Summary: The leadership team comprises individuals with over a decade of experience in their respective fields.
The leadership team at Zerigo Health includes seasoned professionals with extensive experience in healthcare and technology sectors. This depth of experience positions the company well for strategic decision-making and operational execution.
- Clinical Need
-
Aspect: Very Strong
Summary: Zerigo Health addresses a significant unmet need in the treatment of chronic skin conditions.
Chronic skin conditions like psoriasis and eczema affect millions globally, with limited convenient treatment options. Zerigo Health's home-based phototherapy solution offers a compelling alternative to traditional in-clinic treatments, meeting a critical clinical need.
- Competition
-
Aspect: Somewhat crowded
Summary: The market has several players offering treatments for chronic skin conditions.
While Zerigo Health offers a unique connected phototherapy solution, the market includes other companies providing treatments for chronic skin conditions. Differentiation and clear value proposition are essential to capture market share.
- Technical Challenge
-
Aspect: Predictable
Summary: The technology involves established phototherapy methods with predictable outcomes.
Zerigo Health's solution utilizes narrowband UVB phototherapy, a well-established treatment modality. The integration with a connected device adds complexity but remains within predictable technical challenges.
- Patent
-
Aspect: Strong
Summary: The company holds strong patents protecting its technology.
Zerigo Health has secured patents for its connected phototherapy system, providing a competitive edge and protection against potential market entrants.
- Financing
-
Aspect: Well-funded
Summary: The company has secured substantial funding to support its growth.
With a $43 million Series B funding round led by prominent investors, Zerigo Health is well-capitalized to expand its operations and market reach.
- Regulatory
-
Aspect: 510k/PMA
Summary: The product has received necessary regulatory clearances.
Zerigo Health's phototherapy system is FDA-cleared, ensuring compliance with regulatory standards and facilitating market entry.
Opportunity Rollup
- Odds of Success
- 3.3
- Peak Market Share
- 4.3
- Segment CAGR
- 5.4%
- Market Segment
- Medical Devices
- Market Sub Segment
- Dermatology Devices
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.22 |
| 2 | 0.64 |
| 3 | 1.50 |
| 4 | 3.01 |
| 5 | 4.30 |
Key Takeaway
Zerigo Health's connected phototherapy solution addresses a significant clinical need with strong market potential, supported by experienced leadership and substantial funding.